Hillary Iweorah, PA
Physician Assistant · Shelton, CTNPI 1003574997
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 484 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AstraZeneca at 37.4% of the total. Among physician assistant clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 484 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$3K
- Regeneron Healthcare Solutions, Inc.$783
- Amgen$730
- Mylan Specialty L.p.$553
- Boehringer Ingelheim$551
- plus $2K from 27 others
What the payments were for
- Food & beverage$11,985100%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 118 | $4,489 |
| GSK | 134 | $2,575 |
| Regeneron Healthcare Solutions, Inc. | 35 | $783 |
| Amgen | 31 | $730 |
| Mylan Specialty L.p. | 37 | $553 |
| Boehringer Ingelheim | 27 | $551 |
| Inspire Medical Systems, Inc. | 12 | $251 |
| Optinose US, Inc. | 11 | $244 |
| Genentech USA, Inc. | 9 | $230 |
| Sanofi | 10 | $216 |
| Novo Nordisk | 4 | $193 |
| Verona Pharma, Inc. | 4 | $180 |
| Pfizer | 7 | $147 |
| Baxter Healthcare | 5 | $113 |
| Lilly USA, LLC | 5 | $111 |
| Harmony Biosciences LLC | 5 | $101 |
| Electromed, Inc. | 7 | $88 |
| Philips North America LLC | 4 | $55 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $42 |
| Organogenesis Inc. | 1 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| AbbVie | 2 | $37 |
| Merck | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Intra-sana Laboratories | 1 | $21 |
| Insmed, Inc. | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $19 |
| Biogen | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Novartis | 1 | $15 |
| Phadia US Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,987 in reported general payments places this provider in the 95th percentile of 1,795 physician assistant providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $115,203 |
| XolairOmalizumab | 38 | $86,016 |
| Spiriva RespimatTiotropium Bromide | 28 | $33,801 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 29 | $32,630 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 22 | $29,674 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $26,461 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $11,638 |
| Tudorza PressairAclidinium Bromide | 12 | $11,200 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 16 | $5,372 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 114 | $2,576 |
| Levocetirizine Dihydrochloride | 74 | $719 |
| Fluticasone Propionate | 47 | $677 |
| Azelastine Hcl | 17 | $392 |
| Montelukast Sodium | 19 | $150 |
| Azithromycin | 13 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $2,575 | $153,302130 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $551 | $66,43257 claims |
| AstraZenecaBreztri Aerosphere | $4,489 | $29,67422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,795 physician assistant providers in Connecticut.
Other physician assistant in Shelton
- Kristen MagnerShelton$10K
- Gary SpinnerBridgeport$119K
- Jordan MarcouTrumbull$44K
- Mary ElliottGuilford$43K
- Christopher ThompsonGroton$42K
- Michael LalondeNew Haven$35K
- Kristine LaneMiddletown$30K
- Kathryn MidgleyNew Haven$28K
- Richard MoroPlainfield$25K
- Janine TedescoDarien$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.